Dr. Ayesha Cheema is a Primary Care Doctor with Mercy Personal Physicians at Columbia. She offers experienced and thoughtful primary care for adults of Howard County.
Mercy's team of cancer doctors diagnose and treat melanoma, a very serious form of skin cancer.
Dr. David Riseberg, Chief of Medical Oncology and Hematology at Mercy, leads a team of Board Certified physicians who provide compassionate care and comprehensive treatment plans.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials; All Topics of Study
This study is a phase 4 trial evaluating the effect of obeticholic acid on clinical outcomes in patients with primary biliary cholangitis. (302)
The primary aim of the study is to determine whether the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread differs from a healthy, age-matched cohort of the American population. This is a collaborative study with the University of California, San Diego and Rob Knight, PhD who will perform the genetic analysis of bio-specimens from patients who undergo cytoreductive surgery with HIPEC. (Clinical Trials ID #: NCT02599116)
The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery. (Clinicaltrials.gov ID#: NCT03180307)
This study is a phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adult subjects with nonalcoholic steatohepatitis. (AURORA)
The purpose of this study is to compare 2 years of Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone in patients with hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. (Clinicaltrials.gov ID#: NCT02513394)
This is a research study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple‑negative breast cancer. (Clinicaltrials.gov ID#: NCT03498716)
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). This study will help to show whether weight loss programs should be a part of breast cancer treatment. (Clinicaltrials.gov ID#: NCT02750826)
This is a phase II randomized trial evaluate the efficacy and Safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment. (Clinicaltrials.gov ID#: NCT03056755)
This study is a Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study to evaluate safety, tolerability, and pharmacodynamics of PF 05221304 administered daily for 16-weeks to adult subjects with non-alcoholic fatty liver disease.
This study is a phase 2, open label, randomized trial evaluating the effect and safety of MBX-8025 on clinical outcomes in patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid (UDCA).
This is a double-blind, placebo-controlled, randomized phase III study of ipatasertib in combination with paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor–positive, HER2-negative breast cancer (Clinicaltrials.gov ID#: NCT03337724).
This is a single arm, open-label, Phase IIB study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation. (Clinicaltrials.gov ID#: NCT02889900)
A multi-center, randomized, placebo-controlled, double-blind study to confirm the efficacy and safety of terlipressin in subjects with hepatorenal syndrome type I. (The Confirm Study) (MNK19013058)
This study is a phase 2, randomized, double-blind, placebo-controlled, 12-month, multiple-dose study to evaluate the safety, tolerability and efficacy of three dose levels of MSDC-0602K in patients with NASH. (EMMINENCE™)
This is a phase III trial to determine how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy and surgery. (Clinicaltrials.gov ID#: NCT02445391)
This study involves a 1 hour telephone interview to gather information about Smouldering and Multiple Myeloma from a patient’s perspective.
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only. (Clinicaltrials.gov ID#: NCT03053193)
This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. (Clinicaltrials.gov ID#:NCT02488967)
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
This trial compares olaparib versus placebo as adjuvant treatment in patients with BRCA1 or BRCA2 mutations and triple negative breast cancer (ClinicalTrials.gov ID#: NCT02032823)
The purpose of this phase II trial is to determine the toxicity and post-operative complications related to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as an initial treatment option for patients with ovarian, fallopian tube, or primary peritoneal cancers and its impact on quality of life. Subjects will be randomized to one of two treatment groups: CRS with HIPEC followed by combination chemotherapy, carboplatin and paclitaxel, or CRS only followed by combination chemotherapy carboplatin and paclitaxel.
Protocol Title and ClinicalTrials ID#: A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer. NCT02124421
The objective of this study is to collect patient specimens prospectively (tumor, blood, vaginal swab, and urine sample) from benign, high risk, and malignant surgeries in order to develop diagnostic biomarkers and targeted anticancer agents for gynecologic tumors. http://lifegenedna.com/
This study is a phase II, open label, historical controlled study to determine the impact of antibiotic therapy on the disease progression and overall survival of the patients with Pseudomyxoma Peritonei (PMP). The study will examine the use of the antibiotic PREVPAC, in patients undergoing CRS/HIPEC for appendiceal neoplasms with peritoneal dissemination and its effect on patient outcomes and survival. (ClinicalTrials.gov ID#: NCT02387203)
This is a study to define the pathological staging for appendiceal neoplasms by examining mutations of the genetic makeup of tumor tissue and to analyze prognostic factors associated with various stages of appendiceal cancer with peritoneal dissemination.
This is a non-interventional trial for patients receiving palbociclib for their hormone positive advanced breast cancer. (Clinicaltrials.gov ID#: NCT03280303)
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomized, double-blind, placebo-controlled, six-armed parallel group, multi-center, multinational trial.
This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (ClinicalTrials.gov ID#: NCT01674140)
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
This study involves storing specimens from CRS/HIPEC patients with advanced colorectal, gastric, small bowel, primary peritoneal, ovarian cancers, peritoneal mesothelioma, and sarcomas. The purpose is to collect, maintain, and store tissues specimens from CRS/HIPEC and clinical data for future research. The collection of clinical data and outcomes from CRS/HIPEC for advanced intra-abdominal cancers will be used to refine future treatment protocols and enhance patient care.
Sister Helen Amos, RSM was named Executive Chair of the Board of Trustees of Mercy Health Services, Inc. in 1999.
Inspiring stories of Mercy Medical Center patients overcoming tough diagnoses and beating the odds.